Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus FLUDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus FLUDROCORTISONE ACETATE.
BREO ELLIPTA vs FLUDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
0.1 mg orally once daily, range 0.05-0.2 mg/day
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category D/X
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid